Cannabinoids (CBD)

SUDA entered into a feasibility study with Zelira Therapeutics for the use of cannabinoids for a range of uses including insomnia, autism, opioid reduction, anxiety, pain and cancer. The study is expected to take 12 months.

SUDA finalised the Product Development, Licence and Supply Agreement with Cann Pharmaceutical Australia Ltd (CPA) in October 2019. The Agreement is to develop a novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of: drug resistant epilepsy, melanoma and motion sickness throughout the world.